within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AD01_Carmustine;

model Carmustine
  extends Pharmacolibrary.Drugs.ATC.L.L01AD01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01AD01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Carmustine (BCNU) is a nitrosourea alkylating agent used as an antineoplastic (anticancer) drug, mainly for the treatment of brain tumors, multiple myeloma, and lymphomas. It is cytotoxic and works by cross-linking DNA and RNA, thereby inhibiting DNA replication and transcription. Carmustine is approved and still used clinically, particularly for brain tumors due to its ability to cross the blood-brain barrier.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult cancer patients, typical dosing regimen; parameters for intravenous administration.</p><h4>References</h4><ol><li><p>Mali, A, &amp; Bhanwase, A (2025). In vivo pharmacokinetic study of carmustine in rats after giving single-dose of carmustine API solution, flexible liposomes, in situ nasal gel, optimized flexible liposomes embedded in situ nasal gel, and marketed formulation. <i>Annales pharmaceutiques francaises</i> 83(1) 112–123. DOI:<a href=\"https://doi.org/10.1016/j.pharma.2024.09.002\">10.1016/j.pharma.2024.09.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39270836/\">https://pubmed.ncbi.nlm.nih.gov/39270836</a></p></li><li><p>Tyler, JL, et al., &amp; Feindel, W (1986). Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 27(6) 775–780. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3486962/\">https://pubmed.ncbi.nlm.nih.gov/3486962</a></p></li><li><p>Weingart, J, et al., &amp; Dolan, ME (2007). Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 25(4) 399–404. DOI:<a href=\"https://doi.org/10.1200/JCO.2006.06.6290\">10.1200/JCO.2006.06.6290</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17264335/\">https://pubmed.ncbi.nlm.nih.gov/17264335</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Carmustine;
